| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mei Huang, Masakuni Horiguchi, Anna R Felix, Herbert Y Meltze. 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. Neuroreport. vol 23. issue 7. 2012-08-02. PMID:22415605. |
5-ht1a and 5-ht7 receptors contribute to lurasidone-induced dopamine efflux. |
2012-08-02 |
2023-08-12 |
rat |
| Mei Huang, Masakuni Horiguchi, Anna R Felix, Herbert Y Meltze. 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. Neuroreport. vol 23. issue 7. 2012-08-02. PMID:22415605. |
lurasidone is a novel, atypical antipsychotic drug with serotonin [5-hydroxytryptamine (5-ht)]2a, 5-ht7, dopamine (da) d2 antagonist, and 5-ht1a receptor partial agonist properties. |
2012-08-02 |
2023-08-12 |
rat |
| Mei Huang, Masakuni Horiguchi, Anna R Felix, Herbert Y Meltze. 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. Neuroreport. vol 23. issue 7. 2012-08-02. PMID:22415605. |
the ability of lurasidone to reverse the effects of subchronic administration phencyclidine, to impair novel object recognition in rats, an animal model of cognitive impairment in schizophrenia, is dependent, in part, on its 5-ht1a agonist and 5-ht7 receptor antagonist properties. |
2012-08-02 |
2023-08-12 |
rat |
| Mei Huang, Masakuni Horiguchi, Anna R Felix, Herbert Y Meltze. 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. Neuroreport. vol 23. issue 7. 2012-08-02. PMID:22415605. |
we tested whether 5-ht1a partial agonism or 5-ht7 antagonism, or both, contributed to the ability of lurasidone to enhance cortical and hippocampal da efflux, which may be related to its ability to improve cognition. |
2012-08-02 |
2023-08-12 |
rat |
| Mei Huang, Masakuni Horiguchi, Anna R Felix, Herbert Y Meltze. 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. Neuroreport. vol 23. issue 7. 2012-08-02. PMID:22415605. |
further, subeffective doses of the 5-ht1a receptor agonist, tandospirone (0.2 mg/kg), or the 5-ht7 antagonist, sb269970 (0.3 mg/kg), potentiated the ability of a subeffective dose of lurasidone (0.1 mg/kg) to increase da efflux in the prefrontal cortex. |
2012-08-02 |
2023-08-12 |
rat |
| Mei Huang, Masakuni Horiguchi, Anna R Felix, Herbert Y Meltze. 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. Neuroreport. vol 23. issue 7. 2012-08-02. PMID:22415605. |
these findings suggest that the effects of lurasidone on the prefrontal cortex and hippocampus, da efflux are dependent, at least partially, on its 5-ht1a agonist and 5-ht7 antagonist properties and may contribute to its efficacy to reverse the effects of subchronic phencyclidine treatment and improve schizophrenia. |
2012-08-02 |
2023-08-12 |
rat |
| Tomoko Horisawa, Tadashi Ishibashi, Hiroyuki Nishikawa, Takeshi Enomoto, Satoko Toma, Takeo Ishiyama, Mutsuo Taij. The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behavioural brain research. vol 220. issue 1. 2011-07-15. PMID:21277905. |
the effects of selective antagonists of serotonin 5-ht7 and 5-ht1a receptors on mk-801-induced impairment of learning and memory in the passive avoidance and morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. |
2011-07-15 |
2023-08-12 |
rat |
| Beatriz Restrepo, María Luisa Martín, Luis San Román, Asunción Morá. Peripheral 5-HT1A and 5-HT7 serotonergic receptors modulate parasympathetic neurotransmission in long-term diabetic rats. Experimental diabetes research. vol 2010. 2011-07-01. PMID:21403818. |
peripheral 5-ht1a and 5-ht7 serotonergic receptors modulate parasympathetic neurotransmission in long-term diabetic rats. |
2011-07-01 |
2023-08-12 |
rat |
| Albert Adel. Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety. IDrugs : the investigational drugs journal. vol 13. issue 12. 2011-05-02. PMID:21154150. |
lu-aa21004 belongs to a novel chemical class of antidepressant agents, the bisarylsulfanyl amines, and possesses a novel pharmacological profile, with activity at serotonergic receptors 5-ht3, 5-ht7 and 5-ht1a, and also at the 5-ht transporter. |
2011-05-02 |
2023-08-12 |
rat |
| Rosa I Caamaño Tubío, Jorge Pérez-Maceira, Manuel Aldegund. Homeostasis of glucose in the rainbow trout (Oncorhynchus mykiss Walbaum): the role of serotonin. The Journal of experimental biology. vol 213. issue 11. 2010-08-17. PMID:20472767. |
administration of tfmpp (a 5-ht1b agonist) did not increase the plasma levels of glucose, and the hyperglycaemic action of 5-ht was not blocked by antagonists of 5-ht1a (way 100635), 5-ht1d (brl 15572), 5-ht2b (sb 204741) or 5-ht7 (pimozide) receptors. |
2010-08-17 |
2023-08-12 |
Not clear |
| Tadashi Ishibashi, Tomoko Horisawa, Kumiko Tokuda, Takeo Ishiyama, Masaaki Ogasa, Rie Tagashira, Kenji Matsumoto, Hiroyuki Nishikawa, Yoko Ueda, Satoko Toma, Hitomi Oki, Norihiko Tanno, Ikutaro Saji, Akira Ito, Yukihiro Ohno, Mitsutaka Nakamur. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. The Journal of pharmacology and experimental therapeutics. vol 334. issue 1. 2010-07-13. PMID:20404009. |
pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-ht7) and 5-ht1a receptor activity. |
2010-07-13 |
2023-08-12 |
human |
| I Okun, S E Tkachenko, A Khvat, O Mitkin, V Kazey, A V Ivachtchenk. From anti-allergic to anti-Alzheimer's: Molecular pharmacology of Dimebon. Current Alzheimer research. vol 7. issue 2. 2010-06-21. PMID:19939222. |
within serotonergic receptor subtypes, dimebon shows highest affinity for 5-ht7 (ki=8 nm) and 5-ht6 (ki=34 nm) receptors, with the relative affinity rank-order of 5-ht7 > 5-ht6 > or = 5-ht2a = 5-ht2c > 5-ht1a = 5-ht1b > 5-ht2b=5-ht3. |
2010-06-21 |
2023-08-12 |
Not clear |
| Andrea Gogos, Perrin Kwek, Carolina Chavez, Maarten van den Buus. Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors. The Journal of pharmacology and experimental therapeutics. vol 333. issue 1. 2010-04-22. PMID:20042529. |
estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine d1 or d2 or serotonin 5-ht1a, 5-ht2a, or 5-ht7 receptors. |
2010-04-22 |
2023-08-12 |
rat |
| Brian R Noga, Dawn M G Johnson, Mirta I Riesgo, Alberto Pinzo. Locomotor-activated neurons of the cat. I. Serotonergic innervation and co-localization of 5-HT7, 5-HT2A, and 5-HT1A receptors in the thoraco-lumbar spinal cord. Journal of neurophysiology. vol 102. issue 3. 2009-10-23. PMID:19571190. |
i. serotonergic innervation and co-localization of 5-ht7, 5-ht2a, and 5-ht1a receptors in the thoraco-lumbar spinal cord. |
2009-10-23 |
2023-08-12 |
cat |
| Jaime Pei Pei Foong, Joel C Bornstei. 5-HT antagonists NAN-190 and SB 269970 block alpha2-adrenoceptors in the guinea pig. Neuroreport. vol 20. issue 3. 2009-09-08. PMID:19190523. |
however, it was found that the widely used 5-ht receptor antagonists nan-190 (5-ht1a) and sb 269970 (5-ht7) both blocked alpha2-adrenoceptors, and hence depressed inhibitory synaptic potentials and hyperpolarizations evoked by noradrenaline, in these neurons. |
2009-09-08 |
2023-08-12 |
Not clear |
| R Iceta, J E Mesonero, J J Aramayona, A I Alcald. Expression of 5-HT1A and 5-HT7 receptors in Caco-2 cells and their role in the regulation of serotonin transporter activity. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. vol 60. issue 1. 2009-07-20. PMID:19439818. |
expression of 5-ht1a and 5-ht7 receptors in caco-2 cells and their role in the regulation of serotonin transporter activity. |
2009-07-20 |
2023-08-12 |
human |
| Jonathan Shelton, Pascal Bonaventure, Xiaorong Li, Sujin Yun, Timothy Lovenberg, Christine Dugovi. 5-HT7 receptor deletion enhances REM sleep suppression induced by selective serotonin reuptake inhibitors, but not by direct stimulation of 5-HT1A receptor. Neuropharmacology. vol 56. issue 2. 2009-07-01. PMID:18948124. |
5-ht7 receptor deletion enhances rem sleep suppression induced by selective serotonin reuptake inhibitors, but not by direct stimulation of 5-ht1a receptor. |
2009-07-01 |
2023-08-12 |
mouse |
| M Shahid, G B Walker, S H Zorn, E H F Won. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. Journal of psychopharmacology (Oxford, England). vol 23. issue 1. 2009-04-03. PMID:18308814. |
in comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pki) for serotonin receptors (5-ht1a [8.6], 5-ht1b [8.4], 5-ht2a [10.2], 5-ht2b [9.8], 5-ht2c [10.5], 5-ht5 [8.8], 5-ht6 [9.6] and 5-ht7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2a [8.9], alpha2b [9.5] and alpha2c [8.9]), dopamine receptors (d1 [8.9], d2 [8.9], d3 [9.4] and d4 [9.0]) and histamine receptors (h1 [9.0] and h2 [8.2]). |
2009-04-03 |
2023-08-12 |
human |
| M Shahid, G B Walker, S H Zorn, E H F Won. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. Journal of psychopharmacology (Oxford, England). vol 23. issue 1. 2009-04-03. PMID:18308814. |
asenapine behaved as a potent antagonist (pkb) at 5-ht1a (7.4), 5-ht1b (8.1), 5-ht2a (9.0), 5-ht2b (9.3), 5-ht2c (9.0), 5-ht6 (8.0), 5-ht7 (8.5), d2 (9.1), d3 (9.1), alpha2a (7.3), alpha2b (8.3), alpha2c (6.8) and h1 (8.4) receptors. |
2009-04-03 |
2023-08-12 |
human |
| Andrew Holme. Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease. Neuroscience and biobehavioral reviews. vol 32. issue 7. 2009-02-19. PMID:18439676. |
serotonergic modulation of the acute response to stress and the adaptation to chronic stress is mediated by a myriad of molecules controlling serotonin neuron development (pet-1), synthesis (tryptophan hydroxylase 1 and 2 isozymes), packaging (vesicular monoamine transporter 2), actions at presynaptic and postsynaptic receptors (5-ht1a, 5-ht1b, 5-ht2a, 5-ht2c, 5-ht3a, 5-ht4, 5-ht5a, 5-ht6, 5-ht7), reuptake (serotonin transporter), and degradation (monoamine oxidase a). |
2009-02-19 |
2023-08-12 |
mouse |